New isosorbide 5-mononitrate derivative with hypotensive activity
Coppi, G.; Borella, F.; Gatti, M.T.; Comini, A.; Dall' Asta, L.
Bollettino Chimico Farmaceutico 128(2): 74-76
1989
ISSN/ISBN: 0006-6648 PMID: 2775521 Document Number: 337906
Synthesis and pharmacological properties of the 5-fluoro-nicotinic ester with isosorbide-5-mononitrate 3 are reported. The new compound shows an in vitro activity on rabbit aortic helical strips five times higher than isosorbide-5-mononitrate. The hypotensive activity in guinea-pigs of 3 is markedly superior to that of 5-ISMN. In the rat 3 shows a bioavailability and an acute toxicity inferior to those of 5-ISMN after oral administration.
Document emailed within 1 workday
Related Documents
Richard, L.; Klein, G.; Orr, J.M. 1976: Simultaneous measurement of plasma isosorbide dinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate by gas-liquid chromatography Clinical Chemistry 22(12): 2060-2061Atanassova, R.; Balansky, R. 1991: Effects of isosorbide-5-mononitrate and isosorbide-2-mononitrate on isolated dog aorta: vascular relaxation and increase in cyclic GMP Archives Internationales de Pharmacodynamie et de Therapie 312: 104-109
Schneider, W.; Stahl, B.; Kaltenbach, M.; Bussmann, W.D. 1984: Differences in the production of methemoglobin during high-dose treatment with isosorbide dinitrate or isosorbide 5-mononitrate Arzneimittel-Forschung 34(12): 1779-1782
Nakabayashi, S.; Uyama, O.; Nagatsuka, K.; Uehara, A.; Wanaka, A.; Yoneda, S.; Kimura, K.; Kamata, T. 1985: The effect of isosorbide dinitrate and isosorbide-5-mononitrate on prostacyclin (PGI2) and thromboxane A2 (TXA2) generation in rat and human arteries Research Communications in Chemical Pathology and Pharmacology 47(3): 323-332
Lazebnik, L.B.; Tereshchenko, S.N.; Gendel'man, A.M. 1991: Comparison of the clinical and hemodynamic effects of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate in acute myocardial infarction Kardiologiia 31(10): 13-15
Cleophas, T.J.; Niemeyer, M.G.; Zwinderman, A.H.; van der Wall, E.E. 2000: Isosorbide mononitrate 30% immediate-release 70% sustained-release formulation: a review. DUMQOL (DUtch Mononitrate Quality of Life) Study Group Angiology 51(8): 631-638
Sizova, Z.M.; Kozlova, N.V.; Zakharova, V.L.; Shameeva, E.S. 2015: Comparative Assessment of Effects of Isosorbide Dinitrate, Isosorbide-5-Mononitrate and Nicorandil on the Frequency-of Angina Attacks and Vasoregulating Endothelial Function in Patients with Ischemic Heart Disease Kardiologiia 55(2): 10-15
Döring, G. 1992: Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients Journal of Cardiovascular Pharmacology 20(Suppl 3): S74-S81
Pichler, M.; Brandt, D.; Teubl, H.; Dorda, W. 1995: Isosorbide-5-mononitrate in silent ischemia Wiener Klinische Wochenschrift 107(13): 390-395
Wood, S.G.; John, B.A.; Chasseaud, L.F.; Major, R.M.; Forrest, M.E.; Bonn, R.; Darragh, A.; Lambe, R.F. 1984: Metabolic fact of 14C-isosorbide 5-mononitrate in humans Arzneimittel-Forschung 34(9): 1031-1035
Gandini, R.; Cunietti, E.; Assereto, R.; Castoldi, D.; Tofanetti, O.; Baggio, E. 1987: Pharmacokinetics and bioavailability of a new slow-release isosorbide-5-mononitrate system Cardiologia 32(11): 1287-1291
Golikov, A.P.; Allenova, I.B.; El'kina, N.S. 1999: Antianginal effectiveness of regular isosorbide-5-mononitrate (monochinkwe retard) intake Terapevticheskii Arkhiv 71(12): 52-53
Hatanaka, A.R.; Moron, A.F.; Auxiliadora de Aquino, M.M.; de Souza, E.; de Silva Bussamra, L.C.; Araujo Júnior, E.; Mattar, R. 2012: Interruption of a study of cervical ripening with isosorbide mononitrate due to adverse effects Clinical and Experimental Obstetrics and Gynecology 39(2): 175-180
Demin, A.A.; Aksenova, E.A. 2005: Efficacy of isosorbide-5-mononitrate retard in patients with stable exertional angina Klinicheskaia Meditsina 83(9): 53-56
Distante, A.; Lombardi, M.; Moscarelli, E.; Morales, M.A.; L'Abbate, A. 1986: The therapeutic role of isosorbide-5-mononitrate+ in stable and unstable angina pectoris Zeitschrift für Kardiologie 75(Suppl 3): 38-41
Chanrachakul, B.; Herabutya, Y.; Punyavachira, P. 2002: Randomized trial of isosorbide mononitrate versus misoprostol for cervical ripening at term International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics 78(2): 139-145
Zholdin, B.K.; Zaslavskaia, R.M.; Zhamankulov, K.A. 1998: Time-dependent hemodynamic effects of monosan (Isosorbide-5-mononitrate) in anginal patients Klinicheskaia Meditsina 76(4): 30-32
Metelitsa, V.I.; Martsevich, S.I.; Kutishenko, N.P.; Kozyreva, M.P.; Blagodatskikh, S.V.; Simkhaev, L.S.; Slastnikova, I.D.; Vakulovskaia, M.K. 1994: The efficacy of 2 new drug forms of isosorbide-5-mononitrate in patients with stable stenocardia of effort Terapevticheskii Arkhiv 66(8): 22-25
Centonze, F.; Brambilla, M.; Pittana, P.; Serra, G.; Sega, R. 1988: Comparison of steady state pharmacokinetics of isosorbide-5-mononitrate in microgranular formulation or hydrophilic matrix La Clinica Terapeutica 126(3): 195-206
Drummer, C.; Valta-Seufzer, U.; Spannagl, M.; Frey, A.; Lüdke, S.; Schramm, W.; Gerzer, R. 1991: Thrombocyte aggregation and fibrinolysis in healthy probands treated with molsidomine, isosorbide-5-mononitrate and placebo Zeitschrift für Kardiologie 80(Suppl 5): 43-46